From Amgen to Gilead, drugmakers are sitting on billions of cash — and top pharma executives are hinting about big M&A to come in 2019

Billion-dollar deals from drug giants Eli Lilly & Co. and Bristol-Myers Squibb could set the tone for a year full of healthcare acquisitions, analysts and investors say.  Factors like biotech companies’ slumping stocks and last year’s tax cuts could drive the trend, compared with last year’s competitive nature and high premiums.  These are the drugmakers to watch, and what they’ve said so far about M&A. 

Headline deals by drug giants Eli Lilly & Co.

Continue reading...